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ABSTRACT 
Oseltamivir (Tamiflu®; F. Hoffmann-La Roche 
Ltd, Basel, Switzerland) is an orally administered 
antiviral for the treatment and prevention of 
influenza A and B infections that is registered 
in more than 100 countries worldwide. 
More than 83 million patients have been 
exposed to the product since its introduction. 
Oseltamivir is recommended by the World 
Health Organization (WHO) for use in the 
clinical management of pandemic and seasonal 
influenza of varying severity, and as the primary 
antiviral agent for treatment of avian H5N1 
influenza infection in humans. This article is a 
nonsystematic review of the experience gained 
from the first 10 years of using oseltamivir for 
influenza infections since its launch in early 
2000, emphasizing recent advances in our 
understanding of the product and its clinical 
utility in five main areas. The article reviews 
the pharmacokinetics of oseltamivir and its 
active metabolite, oseltamivir carboxylate, 
including information on special populations 
such as children and elderly adults, and the 
co-administration of oseltamivir with other 
agents. This is followed by a summary of data 
on the effectiveness of oseltamivir treatment 
and prophylaxis in patients with all types of 
influenza, including pandemic (H1N1) 2009 
and avian H5N1 influenza. The implications of 
changes in susceptibility of circulating influenza 
viruses to oseltamivir and other antiviral agents 
are also described, as is the emergence of antiviral 
resistance during and after the 2009 pandemic. 
The fourth main section deals with the safety 
profile of oseltamivir in standard and special 
patient populations, and reviews spontaneously 
reported adverse event data from the pandemic 
and pre-pandemic periods and the topical issue 
of neuropsychiatric adverse events. Finally, the 
article considers the pharmacoeconomics of 
oseltamivir in comparison with vaccination 
and usual care regimens, and as a component 
of pandemic influenza mitigation strategies.
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INTRODUCTION
Although the 2009-2010 pandemic outbreak 
raised public awareness of the serious threats 
posed by influenza infections, the burden of 
seasonal influenza infections is probably still 
under-appreciated. It is estimated, for example, 
that up to 20% of people in the United States 
(US) develop influenza each season, and that 
between 3000-49,000 of those infections will be 
fatal, while nearly a quarter of a million influenza 
patients will require hospitalization.1-3 During 
influenza pandemics, the disease burden changes 
with respect to the age group affected. Children 
and younger adults, who are proportionally less 
affected by seasonal influenza epidemics, bore the 
brunt of serious illness and mortality during the 
2009-2010 H1N1 pandemic,4 because they had 
little or no existing immunity to the novel virus. 
Human cases of avian H5N1 influenza, which 
have occurred geographically from South-East 
Asia to the Middle East and Africa, are associated 
with much poorer outcomes than seasonal illness, 
typically causing severe illness which proves fatal 
in nearly 60% of confirmed cases.5
Oseltamivir (Tamiflu®; F. Hoffmann-La Roche 
Ltd, Basel, Switzerland) is an orally administered 
antiviral for the treatment and prevention 
of influenza A and B infections. In adults, it 
is administered as a 75 mg oral capsule, but 
small oral capsules (30 mg and 45 mg) and oral 
suspension formulations are also available for 
use in younger children and renally impaired 
patients. A solution form can also be prepared 
if necessary from the contents of an opened 
capsule (extemporaneous compounding).6,7
Recommended dosages are shown in Table 1. 
For seasonal influenza, oseltamivir is indicated 
for children ≥1 year old and adults of all ages, 
and dosing recommendations for infants <1 year 
old infected with pandemic influenza are also 
provided.6 Oseltamivir is an inactive prodrug: 
its clinically active metabolite is oseltamivir 
carboxylate (OC). In infected individuals, OC 
selectively binds to and inhibits the conserved 
active site of the neuraminidase enzymes that 
are present as major surface antigens on all 
types of influenza viruses. As neuraminidase is 
essential for the release of progeny virions from 
infected cells,8 inhibiting this enzyme limits the 
duration and severity of the infection.
The World Health Organization (WHO) 
revised its guidance on pharmacological 
management of seasonal and pandemic 
Table 1. Recommended oseltamivir dosages for the treatment and prevention of seasonal and pandemic influenza infections 
in children, adolescents, and adults.
Age group Body weight (kg)
Treatment Post-exposure prophylaxis 
5-day course (twice daily) 10-day course (once daily)
Adults; adolescents aged  
≥13 years
– 75 mg 75 mg
Children aged 1-12 years >40 75 mg 75 mg 
>23-40 60 mg 60 mg 
>15-23 45 mg 45 mg 
≤15 30 mg 30 mg 
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influenza in August 2009 in response to the 
developing global influenza pandemic, and these 
guidelines were further revised and simplified 
in February 2010.9 The updated version 
harmonized recommendations with respect to 
antiviral therapies, giving the same advice for 
infection with pandemic viruses as for infection 
with seasonal viruses. For influenza with an 
uncomplicated clinical presentation, prompt 
treatment with neuraminidase inhibitors is 
recommended if patients are at elevated risk of 
severe or complicated disease, including infants 
(particularly those aged <2 years), pregnant 
women, those with chronic respiratory, cardiac, 
or metabolic disorders, and those aged ≥65 
years. For severe or progressive influenza, 
WHO recommends oseltamivir treatment for 
all patients; for immunosuppressed patients, 
WHO advice is to consider using the drug at 
higher doses and/or longer treatment duration, 
depending on clinical response;9 however, UK 
national guidelines recommend zanamivir.10 For 
treatment of influenza caused by viruses known 
to be resistant to oseltamivir, WHO recommends 
zanamivir.9 Earlier WHO guidelines also 
recommend oseltamivir as the primary antiviral 
agent for treatment of confirmed and suspected 
cases of avian H5N1 influenza infection in 
humans; treatment should begin as soon as 
possible, but can be beneficial even in patients 
who present later in the disease course.11,12 Again, 
consideration should be given to higher doses 
and/or longer treatment duration, depending on 
the clinical course of disease.
Following its first regulatory approval 
in Switzerland in 1999, oseltamivir is now 
registered in more than 100 countries worldwide 
as of February 2011, with more than 83 million 
patients having been exposed to the product since 
its introduction. This article is a nonsystematic 
review of some of the experience gained from 
the first 10 years of using oseltamivir in the 
clinical management of influenza infections, 
focusing on the product’s efficacy and safety and 
the effect of emerging resistance to oseltamivir 
and other antivirals. Sections are also included 





As already described, oseltamivir prevents the 
release of progeny virions from cells infected 
by influenza viruses, through inhibition of viral 
neuraminidase by its active metabolite, OC. 
In humans, the standard oseltamivir dosing 
regimen produces a mean minimum plasma 
concentration of the carboxylate metabolite 
of approximately 330 nmol/L.13 The majority 
of virus isolates from all influenza A and 
B subtypes tested thus far are susceptible, 




Many of the key pharmacokinetic characteristics 
of oseltamivir and OC in humans were reported 
in the 1999 article by He and colleagues.13
More recently, a better understanding of the 
pharmacokinetics in special populations has 
been gained. 
Oseltamivir is readily absorbed from the 
gastrointestinal tract after oral administration - it 
readily enters hepatocytes, where it is extensively 
converted (>90%) to the active metabolite, OC, 
by hepatic carboxylesterases, particularly human 
carboxylesterase-1 (HCE-1). The efflux of OC from 
hepatocytes is permeability-limited. No other 
metabolites have been described in humans.
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Maximal concentrations of OC occur at 
approximately 3-4 hours. Plasma concentrations 
of OC are unaffected by co-administration 
with food, and at least 75% of an oral dose of 
oseltamivir reaches the systemic circulation 
as the active metabolite. Once in plasma, OC 
distributes to typical sites of viral infection in 
the upper and lower respiratory tract,13,17 and 
neither oseltamivir nor OC appear to penetrate 
the central nervous system (CNS) to any 
appreciable extent.18 Binding to plasma proteins 
is low (42% for oseltamivir and <3% for OC). OC 
and any remaining small amounts of oseltamivir 
yet to be converted to OC are eliminated 
unchanged in the urine via glomerular filtration 
and tubular secretion (the latter via organic 
anion transporter [OAT-1]). The plasma half-life 
of OC is 6-10 hours, which enables a twice-daily 
dosing regimen.
Intra- and inter-subject variability in plasma 
concentrations of oseltamivir and OC are low and 
the pharmacokinetics of both after single doses 
display linear kinetics at doses of up to 500 mg 
twice daily. Steady-state plasma concentrations 
of OC occur within 3 days of twice-daily dosing, 
with minimal accumulation of oseltamivir and 
less than two-fold accumulation of OC. 
During the development programme, 
both oseltamivir and OC were administered 
intravenously (i.v.) to fully characterize 
individual pharmacokinetics in humans. After 
i.v. OC administration, the half-life of OC is 
only 1-2 hours, whereas after i.v. oseltamivir 
administration, the half-life of OC is comparable 
to that obtained following oral oseltamivir 
dosing. These findings are consistent with the 
need to deliver oseltamivir to hepatocytes, as 
the permeability-limited release of OC from 
these cells enables twice-daily dosing. An 
i.v. formulation of oseltamivir is in clinical 
development and was used during the 2009-2010 
pandemic outbreak in Europe and Australia, 
under compassionate use arrangements (see 
SAFETY section; Intravenous Administration).
Special Patient Populations
The pharmacokinetics of oseltamivir after oral 
administration have been studied in young, 
healthy adults and children, as well as in 
elderly and very elderly subjects.19-21 There 
are no clinically relevant differences between 
pharmacokinetics in healthy volunteers and 
individuals with influenza.13
The main difference between children 
>1 year of age and adults in oseltamivir 
pharmacokinetics is that children aged 
1-12 years clear the active metabolite more 
rapidly than adults, resulting in a lower drug 
exposure for a given dose; however, the exposure-
to-dose ratio in older children (adolescents) 
aged 13-18 years is similar to that in adults.21
The higher clearance rate prompted the 
introduction of an age- and weight-based unit 
dosing system for children, to ensure comparable 
exposures to those in adults and to enable drug 
exposure in children to be maintained within a 
target efficacy/safety window.21
In infants, other considerations when 
identifying a dose range for oseltamivir are 
the rapid development of renal function 
and transporter function that occur early in 
life, as well as the potential for a lower level 
of metabolic activity.22,23 Clinical studies to 
determine the appropriate dosage in infants 
aged <1 year are progressing. Interim results 
from one exposure-targeted study suggest 
that the appropriate oseltamivir doses for 
twice-daily administration are 3.0 mg/kg 
from 0-8 months of age, and 3.5 mg/kg from 
9-11 months of age.24 Another study in 
influenza-infected infants (ClinicalTrials.gov 
identifier: NCT00988325) is exploring the 
suitability of slightly lower dosage regimens, 
ie, 2 mg/kg for neonates up to 1 month old, 
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2.5 mg/kg for those aged 1-3 months, and 
3 mg/kg for those aged 3 months to 1 year, 
all given twice daily. Provisional pooled 
pharmacokinetic data suggest that lower 
body-weight adjusted doses may be needed in 
premature babies (eg, 1.0 mg/kg twice daily),25
although additional data are needed to establish 
a dosing recommendation.
In elderly patients, the exposure-to-dose 
ratio for OC increases, because of age-related 
decline in renal function, but this increase 
is small, relative to the drug’s known safety 
margin, and no dose adjustment is required.19
Pharmacokinetics have not yet been investigated 
in detail in pregnant and lactating women, but 
this is the subject of study in current clinical trials 
(ClinicalTrials.gov identifiers: NCT01203527 and 
NCT01130636). It has been shown in an ex vivo
human placenta model that trans-placental 
transfer of oseltamivir and its active metabolite 
is undetectable at normal therapeutic doses.26 In 
lactating rats, oseltamivir and OC are excreted 
in milk.6,7 Information on lactating women is 
very limited. In a single case report, oseltamivir 
and its carboxylate were detected in breast milk 
collected over 5 consecutive days of treatment 
(75 mg twice-daily dose). Concentrations were 
low and were considered unlikely to have any 
therapeutic significance in the suckling infant.27
As expected for a renally excreted drug, 
exposure to OC increases when renal function 
is impaired, and because patients with severe 
renal insufficiency (creatinine clearance rates 
of ≤30 mL/min) have higher drug exposures 
than those with normal renal function,13 lower 
doses are recommended in such patients.6
The 30 mg capsule formulation facilitates 
dosing in patients with severe renal 
impairment: specifically, the recommended 
dosages in patients with creatinine clearance 
of 10-30 mL/min are 75 mg once daily (or 
30 mg twice daily) for treatment, and 75 mg 
once every other day (or 30 mg once daily) for 
prophylaxis. No dose adjustment is necessary 
for patients with creatinine clearance of 
>30 mL/min. Oseltamivir is not recommended 
for patients with end-stage renal disease 
(creatinine clearance <10 mL/min), although 
a modified oral dosage regimen was shown 
to be well tolerated in hemodialysis (HD) and 
continuous ambulatory peritoneal dialysis 
(CAPD) patients.28 Based on modeling and 
simulation data (Roche, data on file), patients 
undergoing routine HD who develop influenza 
symptoms in the 48 hours between dialysis 
sessions could be given a 30 mg dose before 
dialysis and a 30 mg dose after each dialysis 
session. The oseltamivir dosage does not need 
adjustment in patients with mild to moderate 
hepatic impairment.29 Oseltamivir has 
not been evaluated in patients with severe 
hepatic impairment.
Currently, there are no data to support a need 
for changing oseltamivir dosing on the basis of 
ethnopharmacology or genetic polymorphisms. 
No clinically relevant differences have been 
seen in plasma or cerebrospinal fluid (CSF) 
pharmacokinetics between Japanese and 
Caucasian individuals.18,20 Polymorphisms 
affecting the transporter OAT-1 have been 
reported, but are of low functional significance, 
and although HCE-1 alleles with altered in vitro
functional properties have been described, there 
is no evidence that HCE-1 polymorphisms result 
in clinically relevant changes in the conversion 
rate of oseltamivir to OC in humans.
Co-administration with Other Agents
Oseltamivir has limited potential for clinically 
relevant interactions with other drugs 
commonly administered to influenza patients. 
When oseltamivir was given with amantadine, 
rimantadine, paracetamol, aspirin, antacids, 
cimetidine, amoxicillin, or warfarin, no changes 
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occurred in the systemic exposure of oseltamivir 
or the co-administered drug.13,30-35 Similarly, no 
pharmacokinetic interaction was noted with 
the immunosuppressant drugs cyclosporine, 
mycophenolate mofetil, or tacrolimus in renal 
transplant patients.36 Probenecid, however, 
inhibits tubular secretion of oseltamivir, thus 
increasing the latter’s systemic exposure.34
The potential for this particular interaction to 
allow drug-sparing, ie, reducing the oseltamivir 
dose without compromising efficacy, has been 
explored in more recent studies,37,38 but because 
of concerns about unreliable efficacy, and a 
possible increase in risk of antiviral resistance, 




The inhibition of influenza virus replication by 
oseltamivir, as described in the previous section, 
significantly shortens the course of illness and 
reduces disease severity. The first demonstrations 
of these treatment benefits in clinical practice 
were in patients with seasonal influenza. The 
outcomes of large, randomized, controlled 
trials published in 2000, just after oseltamivir 
was first introduced, showed that a dose of 
75 mg given twice daily for 5 days reduced illness 
duration and symptom severity in adults aged 
18-65 years with influenza A and B infections.39,40
The study by Treanor et al.39 also showed that 
treatment reduced the incidence of secondary 
complications and the need for antibiotics in 
adults; benefits which were also demonstrated 
when data from the Treanor and Nicholson40
trials were pooled with data from eight other 
studies in adults, adolescents, and elderly adults 
(>65 years old);41 this pooled analysis also 
demonstrated a reduced risk of hospitalization. 
With respect to the prevention of seasonal 
influenza, efficacy of oseltamivir was 
demonstrated both as post-exposure prophylaxis 
(PEP; 75 mg once daily for 7 or 10 days) and 
seasonal prophylaxis (a 6-week course at the 
same dosage). In the PEP setting, significant 
reductions in the incidence of clinical illness 
were reported both in a study of household 
contacts (adults and adolescents) of untreated 
index cases with influenza-like illness (ILI), ie, 
a reduction of 89% (P<0.001),42 and a study of 
138 households where index cases with ILI were 
treated, in which the protective efficacy against 
confirmed influenza in adults and children was 
58.5% (P<0.05).43 Seasonal prophylaxis with 
75 mg oseltamivir once daily for 6 weeks reduced 
the incidence of clinical illness in adults by 
76% (P<0.001)44 and in elderly residents of 
nursing homes by 92% (P<0.01).45
Children
Treatment with oseltamivir produces a similar 
range of benefits in children aged 1-12 years, 
including a reduction, relative to placebo, in 
the duration of fever and in the number of 
secondary infections, notably otitis media.46,47
In the study by Hayden et al.,43 mentioned 
above, which evaluated the prevention of disease 
transmission, the household contacts included 
107 children aged 1-12 years who received 
weight-based unit doses of oseltamivir 30-60 mg 
once daily as PEP for 10 days; a separate analysis 
of this group showed a protective efficacy against 
influenza of 55%. In a subsequent open-label 
study, none of the 49 children aged 1-12 years 
who received oseltamivir as seasonal prophylaxis 
(weight-based unit doses of 30-75 mg once daily 
for 6 weeks) developed laboratory-confirmed 
clinical influenza, although this study was not 
designed to show prophylactic efficacy.48
In the randomized controlled trial of 
oseltamivir in children aged 1-12 years, separate 
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analysis of 144 children with influenza B 
infection showed significantly reduced duration 
of fever and other symptoms compared with 
placebo.46 More recently, a Japanese group 
reported that fever responded more slowly 
to oseltamivir in children with influenza 
B infections than those with influenza A 
infections,49 although a later trial by the same 
group that studied oseltamivir and zanamivir 
found that the speed of fever resolution in 
treated children was similar for influenza B and 
influenza A/H1N1 infections, but slightly faster 
for influenza A/H3N2 infections.50
High-risk Population Groups
Evidence from prospective and retrospective 
studies in a range of clinical settings showed that 
patients at higher risk of complications from 
influenza infection, such as young children, 
patients with cardiac and/or respiratory 
disorders, and immunocompromised adults 
achieve clinical benefits, such as reduced risk 
of pneumonia and asthma exacerbations.51-56
Moreover, oseltamivir treatment was associated 
with reductions in mortality risk in hospitalized 
patients with severe or complicated seasonal 
influenza, reducing risk by 79% in adults 
in a Toronto hospital study and by 73% in a 
Hong Kong hospital study, compared with no 
antiviral treatment.57,58
Systematic Reviews and Meta-analyses
The published evidence on the efficacy of 
oseltamivir in the treatment and prophylaxis of 
seasonal influenza has been extensively reviewed 
at various stages through the first 10 years 
of oseltamivir use.59-63 A 2009 Cochrane 
review of the use of neuraminidase inhibitors 
in adults failed to show a beneficial effect 
of oseltamivir on influenza complications 
based on data from four published studies.62
A subsequent independent re-analysis of 
11 randomized controlled trials on oseltamivir, 
including unpublished studies that were not 
included in the Cochrane review, concluded that 
oseltamivir reduced the risk of lower respiratory 
tract complications which required antibiotic 
treatment by 28% (95% CI, 11%-42%).64
A review published in the Cochrane database in 
2007 concluded that neuraminidase inhibitors 
reduced the incidence of complications in 
children, and were effective for reducing illness 
duration in healthy children, although illness 
duration in children with asthma was not 
reduced significantly.61
Timing of Treatment
From trials in patients with uncomplicated 
seasonal influenza, it was clear that treatment 
with oseltamivir was most effective when 
given early in the course of infection.65-67 For 
example, in children aged 1-3 years, oseltamivir 
substantially reduced the median time to 
resolution of illness by 3.9 days (vs. placebo) 
(P=0.006) in unvaccinated children with 
influenza A when given within 24 hours, and 
reduced the incidence of acute otitis media by 
85% in children with influenza A or B when 
given within 12 hours.67 It has since been shown 
that this greater advantage of early treatment 
applies not only in cases of milder illness, but 
also in serious seasonal influenza infections in 
hospitalized patients (and similar infections 
with avian H5N1 and pandemic H1N1 viruses, 
as described later in this review). Lee et al.58
showed that treatment within 2 days of illness 
onset was associated with earlier discharge from 
hospital and faster discontinuation of oxygen 
therapy than patients who received late or no 
treatment. Moreover, this study also showed that 
treatment started within 4 days of illness onset 
was associated with a significant improvement 
in survival compared with patients who received 
later or no treatment.58
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Avian H5N1 Influenza 
Human infections with avian H5N1 influenza 
have been much more geographically restricted 
than seasonal influenza cases, and only 508 
confirmed cases had been reported to WHO by the 
end of November 2010; however, H5N1 strains are 
much more virulent than seasonal strains, with 
302 patients with confirmed infection (59.4%) 
having died of the disease up to that date.5
Antiviral drugs, principally oseltamivir, have 
been used to treat affected patients, and pooled 
data from uncontrolled studies from 12 countries 
strongly suggested that oseltamivir treatment 
could reduce mortality.12,68 The WHO authors 
suggested, however, that treatment might be more 
effective at higher doses than used for seasonal 
influenza, a view shared by other researchers.69
Starting treatment as quickly as possible after 
the onset of illness was also shown to be crucial 
to improving survival probability,68,69 which 
can prove more challenging than in seasonal 
influenza management, because nonspecific 
symptoms in the first 2 days of illness can delay 
diagnosis.70 More recent reports on experience in 
Vietnamese patients support the earlier findings 
in demonstrating improvement in survival after 
oseltamivir treatment,71,72 and evidence that 
prophylactic use of the drug may prevent spread 
of human infection, not only for H5N1 influenza, 
but also disease caused by the H7N7 strain, was 
described in a recent review by Smith.73
The newest data to be published on 
treatment experience are those from the 
Roche-sponsored Avian Influenza Expert 
Group (AVEX) Avian Influenza Registry, which 
allows physicians from any country to upload 
new clinical data to an online database.12
The report analyzes data from 308 adults 
and children with human avian influenza in 
12 countries, 45% of whom were male and whose 
median age was 17 years (range: 1-75 years; 
46% aged <16 years). Oseltamivir was the 
sole treatment for 150 patients, and for 134 
other patients no receipt of an antiviral 
was documented. Crude survival rates were 
significantly better in patients who received at 
least one dose of oseltamivir (90/150 [60%]) 
than in the no-antiviral treatment cohort 
(32/134 [24%; P<0.0001; Figure 1]). Analysis 
of 221 patients for whom timing of treatment 
relative to symptom onset was known showed 
that the advantage of oseltamivir over no 
antiviral treatment was largest in those who 
began treatment within 2 days of onset 
(survival rates: 15/18 [83%] and 19/95 [20%], 
respectively; relative risk [RR] for survival = 4.17 
[95% CI, 2.65-6.55; P<0.0001]). In patients 
who began treatment within 3-5 and 6-8 days 
of onset also, survival was significantly better 
in oseltamivir recipients than in those who 
received no antiviral treatment [48% vs. 27% 


















Days from presentation for treatment to death
No antiviral treatment Oseltamivir treatment
Figure 1. Kaplan-Meier survival curves showing receipt 
of oseltamivir compared with no antiviral treatment.12 
Reproduced with permission from Adisasmito W, Chan PK, 
Lee N, et al. Effectiveness of antiviral treatment in human 
influenza A(H5N1) infections: analysis of a Global Patient 
Registry. J Infect Dis. 2010;202:1154-1160.
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Pandemic (H1N1) 2009 Influenza 
A novel H1N1 influenza virus first isolated in 
humans in April 2009 in Mexico reached “global 
pandemic” status by June 11, 2009, the first 
pandemic of this type since 1969, and caused 
disease outbreaks in most countries throughout 
the world by March 2010.4 The illness caused 
by the pandemic (H1N1) 2009 virus was mild 
in most cases, but as with seasonal influenza, 
severe symptoms and complications were seen 
in many patients, and at least 18,450 deaths 
were reported by early August 2010.4,74 Although 
hospitalization rates were highest in patients 
aged <5 years, fatality rates in hospitalized 
patients appear to have been low in children, 
and highest in those aged ≥50 years.4 Thus far, 
published studies on the efficacy of oseltamivir 
in pandemic (H1N1) 2009 influenza have 
mostly reported experience in patients with 
severe illness, although virological findings in 
patients with milder disease course have also 
been published. 
Viral Clearance
In China, Singapore, and Vietnam, a 
containment measure used in the early stages of 
the pandemic (H1N1) 2009 influenza outbreak 
was to isolate all patients with confirmed 
infection in hospital, even those with mild 
illness. Three studies in this setting showed that 
prompt oseltamivir treatment was associated 
with a shorter duration of viral shedding 
compared with those who started treatment at 
a later stage of illness;75-77 results of these studies 
are summarized in Table 2. In 167 of 179 (93.3%) 
Table 2. Summary of viral clearance results from cohorts of patients with mild pandemic (H1N1) 2009 influenza admitted 
to hospital for quarantine purposes, and where timing of oseltamivir treatment relative to illness onset was recorded.
Country of studyreference Population studied Outcomes 
China75 Quarantined patients (n=145; mean age 
20.6 years; 76 aged <18 years): 118 received 
oseltamivir (83 within 48 hours of illness 
onset); 27 refused treatment
Faster mean rate of viral load reduction in 
patients starting oseltamivir within 48 hours 
(−0.638 log10 copies/mL/day post-symptom 
onset; 95% CI, −0.809 to −0.466) than in 
untreated patients (−0.409, 95% CI, −0.663 to 
−0.185)
China76 Quarantined adults and children (n=426; 
mean age 23.4 years, 115 aged <15 years); 351 
received oseltamivir (254 within 48 hours of 
illness onset)
Greater risk of prolonged viral shedding in 
patients starting oseltamivir >48 hours after 
illness onset than in those starting within 
48 hours (OR = 4.46, 95% CI, 2.58-7.72; 
P<0.001)
Singapore77 Quarantined individuals (n=70; median 
age 26 years; IQR, 21-38 years); all received 
oseltamivir (36 within 48 hours of illness 
onset) 
Median duration of viral shedding (5.0 days; as 
measured by PCR testing) significantly shorter 
in patients starting treatment on days 1-3 of 
illness than those starting on day 4 or later 
(>7.0 days; P<0.05). Two days after finishing 
oseltamivir course, viral shedding detected in 
significantly fewer patients treated early (8/36) 
than patients treated later (18/34; P=0.01).
IQR=interquartile range; OR=odds ratio; PCR=polymerase chain reaction.
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quarantined patients with mild pandemic 
H1N1 influenza in Vietnam, viral clearance as 
measured by reverse transcription polymerase 
chain reaction (RT-PCR) testing of respiratory 
samples was achieved 1 day after completion of 
5 days oseltamivir treatment, and no virus could 
be isolated from any samples taken on or after 
that day.78 These findings agree with results of 
studies in seasonal influenza, both in hospitalized 
patients and those with milder disease.40,79
Clinical Outcomes: Treatment
Common features of the severe form of 
pandemic (H1N1) 2009 influenza seen 
worldwide were respiratory complications, such 
as pneumonia and acute respiratory distress 
syndrome (ARDS), requiring mechanical 
ventilation and intensive care unit (ICU) 
treatment.80-82 In line with findings of studies in 
severe seasonal and avian influenza, reports on 
cohorts of patients hospitalized with pandemic 
(H1N1) 2009 influenza (including patients 
in the ICU) demonstrate favorable outcomes 
in patients who received prompt antiviral 
treatment, including reduced risk of mortality, 
ICU admission, and respiratory failure, as well 
as a reduced need for mechanical ventilation. 
There was also a consistent association between 
starting treatment within 48 hours of symptom 
onset and better outcomes. Studies that have 
Table 3A. Summary of outcomes from cohort studies and case series in adults hospitalized with severe pandemic (H1N1) 
2009 influenza where early antiviral treatment (relative to illness onset) was compared with later treatment.
Country of studyreference Population and treatment Outcomes
Taiwan83 Adults and children (median age, 18 years 
[range, 0.8 months-73 years]) with pneumonia 
(n=96); all received oseltamivir (numbers 
starting treatment >48 hours and <48 hours 
after symptom onset not stated)
Higher risk of respiratory failure in patients 
starting oseltamivir >48 hours after symptom 
onset compared with patients starting within 
48 hours (multivariate analysis: OR = 16.1, 
95% CI, 1.9-14.3; P=0.011)
US84 Adults and children (n=99; 58 aged
<18 years); 36 received oseltamivir within 
48 hours of symptom onset; 40 received 
oseltamivir later than 48 hours
Longer median duration of hospitalization in 
patients starting oseltamivir later than earlier:  
3 days versus 2 days; P=0.03
UK85 Adults and children (n=2416; median age,  
20 years); 1299 known to have received 
antivirals, of whom 617 started treatment 
within 48 hours of symptom onset
Risk of admission to ICU was significantly 
lower in those treated with antivirals within  
48 hours of symptom onset than those who 
started treatment later than that (OR = 0.68; 
95% CI, 0.47-0.99)
US86 Adults and children (n=47, median age,  
43 years) with fatal severe pandemic influenza, 
32 of whom received oseltamivir
Outcomes compared for 28 who were admitted 
to ICU and died after >24 hours in hospital 
and 95 control patients (= hospitalized and 
survived); no data on age, number treated or 
timing of treatment in these two subsets
Patients who died started oseltamivir treatment 
later than surviving patients (medians, 6.5 and 
3 days; P<0.01)
Among those who received oseltamivir, 
relatively fewer patients who died started 
treatment within 48 hours of illness onset 
(15%) compared with patients who survived 
(49%, P<0.01)
ICU=intensive care unit; OR=odds ratio; RR=relative risk; UK=United Kingdom; US=United States.
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compared the effect of early treatment initiation 
with a control group have shown treatment 
benefit in adult patients (Table 3A)83-86 as well 
as in vulnerable sub-populations, ie, infants, 
pregnant women, and immunosuppressed 
individuals (Table 3B).81,87-90
Further support for the value of oseltamivir 
in treating pandemic (H1N1) 2009 influenza 
comes from four other studies. In an analysis of 
58 critically ill patients with confirmed, probable, 
or suspected pandemic influenza A (H1N1), 
24 of whom died within 60 days, neuraminidase 
inhibitor treatment was associated with a 
better survival risk than no antiviral treatment 
(OR = 8.5 [95% CI, 1.2-62.8]; P=0.04), after 
excluding patients who died within 72 hours 
and so had less opportunity for treatment; 
45 patients received one or more neuraminidase 
inhibitors (oseltamivir, 44; zanamivir, 6).82
In a retrospective study of patients who 
were hospitalized with pandemic influenza for 
at least 24 hours, 200 of 272 received antivirals 
Table 3B. Summary of results from cohort studies and case series in high-risk patients hospitalized with severe pandemic 
(H1N1) 2009 influenza where timing of antiviral treatment relative to illness onset was recorded. 
Country of studyreference Population studied Outcomes
Argentina81 Infants and children in ICU (n=147);  
135 received oseltamivir
Oseltamivir initiation within 24 hours was 
associated with lower risk of death (OR = 0.20, 
95% CI, 0.07-0.54; P<0.01)
US87 Pregnant women (n=94); 30 received antivirals 
(mostly oseltamivir) within 48 hours of 
symptom onset; 30 received antivirals later 
than this
Higher risk of death or ICU admission in 
patients starting antivirals later (RR = 4.3, 95% 
CI, 1.4-13.7)
US88 Pregnant women (n=788) of whom 509 
received antivirals (476 oseltamivir alone). 
Timing of antiviral treatment known for 384: 
219 within 48 hours of illness onset, 84 on days 
3 and 4, and 81 on day 5 or later 
Patients starting antivirals on day 5 or later had 
higher risk of mortality (RR = 53.5, 95% CI, 
7.3-391.7), ICU admission (RR = 6.0, 95% 
CI, 3.5-10.6) and mechanical ventilation (RR 
= 12.3, 95% CI, 5.4-27.7) than those starting 
within 48 hours (P<0.001 for all)
US89 Pregnant women (n=62); 53 received 
oseltamivir (30 within 48 hours of symptom 
onset; 14 on day 3 or 4; nine on day 5 or later)
Eight women had severe illness: one (3.3%) 
woman who started treatment within 48 hours, 
three women (21.4%) who started treatment on 
day 3 or 4, and four (44.4%) who started later 
(P=0.002 for trend by non-parametric test).
US and Canada90 Solid organ transplant recipients with 
compromised immune function (n=237; 
median age 32 years [range, 1-95 years]); 
223 received neuraminidase inhibitors 
(oseltamivir in 221), 90 within 48 hours of 
symptom onset 
Significant association between early antiviral 
treatment and absence of need for hospital 
admission (P=0.049), ICU admission 
(P=0.007), and mechanical ventilation 
(P=0.019)
Nine deaths: 1/90 (1%) in patients starting 
antivirals within 48 hours and 8/125 (6%) in 
those starting antivirals later (P=0.059)
ICU=intensive care unit; OR=odds ratio; RR=relative risk; UK=United Kingdom; US=United States.
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(188 of whom were on oseltamivir). Multivariate 
analysis showed receipt of antiviral drugs within 
2 days of onset of illness to be the only variable 
significantly associated with a positive disease 
outcome.80 Surveillance of 1088 patients with 
severe illness found that substantially higher 
proportions of those that survived had received 
antiviral treatment within 48 hours of symptom 
onset, compared with those who died, but the 
authors did not report the number of patients 
who received oseltamivir, and did not test for 
statistical significance of the differences between 
fatal and non-fatal cases.91 Favorable outcomes 
were also reported in patients with mild 
influenza: in approximately 4570 patients with 
confirmed pandemic (H1N1) 2009 influenza 
who received prompt antiviral treatment 
(oseltamivir, 99.4% of cases) after presenting to 
emergency rooms, 11 needed ICU treatment and 
none died.92
Retrospective analysis of cases reported to 
the French public surveillance system suggested 
a protective effect of early antiviral treatment, 
with those receiving oseltamivir within 48 hours 
of illness onset being significantly less likely 
to develop serious infection or to die than 
those treated later or not at all,93 and a similar 
association was shown in a Canadian case-
control study, in which patients treated within 
48 hours of illness onset had a lower probability 
of admission to hospital or ICU than those 
treated more than 48 hours after onset.94
Clinical Outcomes: Prophylaxis
Preventing disease spread in the early stages 
of the pandemic outbreak was a priority 
in many national management plans, and 
outcomes of containment strategies involving 
oseltamivir prophylaxis were reported in 
detail by three groups.
A ring prophylaxis intervention strategy was 
used to contain outbreaks of pandemic (H1N1) 
2009 influenza in four Singapore military units: 
this entailed isolating index cases (confirmed 
infections), segregating affected units from 
others, and giving all co-workers of the index 
case (1100 of 1175 at-risk personnel) oseltamivir 
75 mg daily for 10 days.95 Infection rates were 
significantly lower after the intervention 
than beforehand based on reduction of the 
reproductive number (R0; number of new cases 
attributable to the index case), whether based on 
confirmed cases only (1.91-0.11) or confirmed 
and untested symptomatic cases (1.85-0.28; 
P<0.001 for both analyses). Before and after 
the intervention, the total individuals infected 
were 75 (6.4%) and seven (0.6%), respectively. 
Oseltamivir was well tolerated, with no serious 
adverse events (AEs) reported.95
The other two groups investigated disease 
transmission from index cases to household 
contacts. The first study related to the first 
outbreak of pandemic (H1N1) 2009 influenza in 
Osaka, Japan.96 The secondary attack rate (SAR) 
in 379 contacts from 124 separate households 
was determined according to whether contacts 
received PEP (n=333) or not (n=46); of those 
receiving PEP, 232 (69.7%) took oseltamivir, 
62 (18.6%) took zanamivir, two took both, 
and 36 received an un-named drug. Two of 
the 14 contacts who developed influenza were 
in the PEP group and 12 in the no-PEP group, 
producing estimated SARs of 26.1% and 0.6%, 
respectively, and a RR of transmission of 0.023 
(95% CI, 0.005-0.100; P<0.001).96 The second 
group reported on transmission of pandemic 
(H1N1) 2009 influenza from 65 Hong Kong 
schoolchildren to 205 household contacts.97
Twelve contacts developed influenza, giving an 
estimated SAR of 5.9% (95% CI, 2.7-9.1) for all 
contacts; however, the SAR for the group who 
did not receive oseltamivir prophylaxis was 8.5% 
(12/141 contacts), and for contacts who did 
receive prophylaxis was 0% (0/64; 95% CI, 0-0.9). 
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The authors gave no details on either the dosage 
of oseltamivir or its tolerability.97
RESISTANCE
Implications and Mechanism
OC binds to the influenza neuraminidase active 
site and inhibits neuraminidase enzyme activity 
- this reduces the ability of the influenza virus to 
migrate through lung mucus layers and reduces 
the rate of release of new influenza virions from 
infected cells. These changes limit the spread 
of virus infection and reduce the duration and 
severity of the infection. The susceptibility of 
influenza virus neuraminidase to inhibition by OC 
can be increased (hypersusceptibility) or decreased 
(resistance) by mutations in the neuraminidase 
coding sequence. Such genetic mutations may 
arise naturally through spontaneous mutation, 
or may be drug-induced, when virus replication 
occurs under selection pressure in the presence of 
a neuraminidase inhibitor. 
Changes in the susceptibility of viral 
neuraminidase to inhibition by neuraminidase 
inhibitors are related to changes in inhibitor 
binding affinity to the enzyme active site: 
mutations that increase inhibitor binding 
affinity can increase susceptibility of 
neuraminidase to inhibition, whereas mutations 
that decrease inhibitor binding affinity can 
reduce susceptibility and may confer resistance 
to inhibition. The most common OC resistance 
mutation is the H275Y mutation (where 
tyrosine replaces histidine at position 275 on 
the N1 subtype neuraminidase). The degree 
of resistance to oseltamivir conferred by this 
mutation is specific to influenza subtype, ie, 
resistance occurs in N1 neuraminidase subtypes, 
such as H1N1 or H5N1 viruses, but not in other 
subtypes, such as H3N2 or influenza B viruses. 
The H275Y mutation also confers resistance 
in a drug-specific manner. While N1 subtype 
neuraminidases are highly resistant to inhibition 
by OC, this mutation does not affect inhibition 
of neuraminidase by zanamivir. Other mutations 
confer resistance specifically to other virus 
subtypes or to other neuraminidase inhibitors, 
such as zanamivir and peramivir. 
As the neuraminidase active site is highly 
conserved and essential for virus replication, 
mutations that confer neuraminidase inhibitor 
resistance often affect the replication fitness and 
transmissibility of viruses,98 and have therefore 
been rare in circulating influenza virus strains. 
An exception was an H1N1 virus that emerged 
in Europe in 2007 that carried the H275Y 
resistance mutation in a compensatory sequence 
background, and became the predominant 
H1N1 strain for two influenza seasons. Studies 
have indicated that the replication fitness and 
transmissibility of H1N1 and H5N1 virus strains 
carrying the H275Y mutation can vary. 
The clinical presentation of influenza in 
immunocompetent patients who are infected 
with oseltamivir-resistant H1N1 viruses is 
very similar to disease caused by oseltamivir-
susceptible viruses, and the frequencies of 
secondary complications and outcomes also 
appear to be similar.99,100 To date, all cases of 
drug-induced resistance in immunocompetent 
patients have been observed only transiently 
during the infection, and the virus in question 
was eventually cleared with no evidence of 
transmission. However, close monitoring of 
sequence evolution and emergent resistant 
viruses with different sequence backgrounds is 
essential to enable early recognition of trends 
towards increased fitness, transmissibility 
or pathogenicity of viruses that result from 
antigenic drift. Antiviral resistance may emerge 
more often in immunocompromised patients 
who require a prolonged treatment duration; 
in these patients, and in patients infected 
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with highly pathogenic viruses such as H5N1, 
resistance poses a higher risk than normal - such 
patients should be intensively monitored for 
resistance emergence during treatment. 
Drug-Induced Resistance Versus Natural 
Resistance
Drug-induced resistance is defined as the 
emergence of a drug-resistant virus isolate in a 
treated patient who was infected with a drug-
sensitive virus before treatment. In contrast, 
the term natural resistance is used to describe 
the emergence of a drug-resistant virus in an 
individual who has not been exposed to drug or 
been in close contact with somebody who has 
received drug treatment. 
Drug-induced resistance selection during 
treatment of immunocompetent persons with 
oseltamivir is currently rare. As reviewed in an 
article by Aoki and colleagues,98 the rate of drug-
induced resistance found in Roche-sponsored 
clinical trials in seasonal influenza virus 
infections was low. In all, 0.4% of adults (5/1245) 
and 5.4% of children (25/464) had detectable 
oseltamivir-resistant virus at one or more time 
points during treatment.98 The rate of resistance 
in children was higher in two studies (9/50 
[18.0%] and 7/43 [16.3%], respectively) in which 
suboptimal doses were given.101,60 In a small study 
of children who received oseltamivir at standard 
weight-based dosages during 2005-2007, 
overall drug-induced resistance incidence was 
6.3% (4/64), similar to the overall incidence 
reported by Aoki and colleagues. Breakdown of 
resistance incidence by virus subtype was 27.3% 
(3/11) for H1N1 strains, 2.9% (1/34) for H3N2, 
and 0% (0/19) for influenza B. The significance 
of the apparent increased rate of resistance in 
H1N1 virus infections in children remained 
unresolved because of the small number of cases, 
but nevertheless suggests a possibility of subtype 
or strain-specific differences in the barrier 
to resistance.102
The results from worldwide surveillance 
of oseltamivir resistance are consistent with 
a relatively low incidence of resistance in 
controlled clinical studies. While 36 million 
courses of oseltamivir were prescribed in Japan 
from its introduction in 1999 through to 2007,103
99.7% of viral isolates tested in Japan between 
2003 and 2007 were susceptible to oseltamivir,104
and a similar proportion of susceptible strains 
(99.7%) was found by worldwide surveillance 
between 1999 and 2002.105
Notably, a global surveillance report in early 
2008 found a very low rate of resistant mutations 
in samples from 2004-2007, but also recorded 
a pronounced increase in incidence of H1N1-
H275Y viruses in a preliminary analysis of 
2007-2008 isolates, with an incidence of 
resistance in all samples of 6.4% (57/896 isolates), 
most coming from the US.106 The 2007-2008 
and 2008-2009 winter seasons in the northern 
hemisphere and the 2008 season in the southern 
hemisphere were marked by the emergence of 
a naturally-resistant influenza A H1N1-H275Y 
virus, which was first described in Norway in 
2007 and then became the predominant H1N1 
virus strain worldwide from the middle to the end 
of 2008, although H3N2 and B virus infections 
were also prevalent during this time. This new 
H1N1 virus replaced the previous seasonal H1N1 
virus in Europe, reaching an overall prevalence of 
24% (712/2948 isolates tested) of H1N1 isolates 
in the 2007-2008 season. In that season, 60% 
of collected samples in Europe were influenza A 
and 40% influenza B, with 96% of the influenza 
A samples being the H1 subtype: thus, 14% of 
influenza virus infections in Europe were with 
oseltamivir-resistant virus, and 86% of infections 
with oseltamivir-sensitive virus.107
A study during the 2007-2008 season found 
that the prescription rate for oseltamivir in 
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12 European countries had not risen from 
the average level of the previous 6 years, 
and that there was no correlation between 
the oseltamivir prescription volumes and 
prevalence of the 2007 H1N1-H275Y virus, 
consistent with the emergence and spread of 
resistance to oseltamivir in these viruses that 
was independent of drug use.108 While the 
European influenza season of 2007-2008 was 
dominated by influenza A (H1N1) and influenza 
B infections, the following season (2008-2009) 
was mostly associated with influenza A 
(H3N2) infections. Of 3696 isolates collected 
between week 40 of 2008 and week 19 of 2009, 
2564 (69.4%) were H3N2, 166 (4.5%) were 
H1N1, 965 (26.1%) were influenza B, and there 
was a single isolate of new pandemic influenza 
H1N1 (2009); so despite 98%-99% of seasonal 
H1N1 sequences being oseltamivir-resistant 
H1N1-H275Y, more than 95% of influenza 
virus infections in Europe during the 2008-2009 
season were with oseltamivir-sensitive H3N2 
or B viruses.109 The switch in prevalence in the 
US over the same two seasons, however, was 
the reverse of that in Europe: 2007-2008 was 
H3N2-dominated and 2008-2009 was H1N1-
dominated. Moreover, the spread of the naturally 
oseltamivir-resistant H1N1-H275Y variant in the 
US was slower than in Europe, with a prevalence 
among H1N1 isolates of 12.3%.99 Only 2.3% of all 
influenza infections in the US during 2007-2008 
were with oseltamivir-resistant viruses, but 
this changed markedly in 2008-2009, when 
approximately 60% of influenza infections 
were with H1N1 viruses, 99% of which were 
the H1N1-H275Y strain; the remaining 40% of 
influenza viruses (mostly type B) were sensitive 
to inhibition by oseltamivir.110
For this H1N1-H275Y virus variant to 
emerge, with a sufficiently high replication 
capacity to permit onward transmission, the 
presence of a permissive sequence background 
was required, and a number of candidate 
mutations in neuraminidase (H45N, K78E, 
E214G, R222Q, G249K, T287I, K329E, D344N, 
D382N) were described by Rameix-Welti et al.111
using sequence analysis. This group reported a 
significant increase in neuraminidase binding 
affinity for sialic acid substrate among the 
earlier oseltamivir-sensitive viruses from the 
2007-2008 season, which may have affected 
fitness, while the introduction of the H275Y 
mutation reduced binding affinity to more 
typical H1N1 levels, and may have restored 
more optimal balance between hemagglutinin 
and neuraminidase binding affinities for sialic 
acid substrates.111 It was recently shown that the 
presence of the H275Y mutation can reduce the 
amount of neuraminidase that reaches the cell 
surface during protein synthesis, and that some 
of the candidate compensatory mutations could 
reverse that defect.112
Natural variation of the neuraminidase 
sequence is mostly driven by antigenic 
drift (immune selection), as neuraminidase, 
like hemagglutinin, is targeted by the host 
immune response. As influenza viruses evolve 
to circumvent host immune response and 
immune memory, specific antigenic patterns 
may be maintained only for a limited time 
period before being replaced by new virus 
variants. Thus, when global population 
immunity has reached a threshold level that 
will prevent productive spread of the H1N1-
H275Y virus, antigenic drift is expected to lead 
to its replacement by an antigenically different 
H1N1 virus, also driven by immune selection. 
For example, northern hemisphere seasons 
dominated by H1N1 virus infections have 
generally been followed by H3N2-dominated 
seasons, as was observed in 2007-2008 and 
2008-2009 in Europe. The oseltamivir-resistant 
seasonal H1N1 virus has now been almost 
completely replaced by pandemic H1N1 
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(2009) virus, which became the dominant 
virus in the 2009-2010 season worldwide. 
Early indications are that the 2010-2011 
season may see an increase in H3N2 infections, 
consistent with widespread global exposure and 
immunity to pandemic (H1N1) 2009 virus. 
Resistance in Avian Influenza Viruses 
To date, resistance to oseltamivir in avian H5N1 
viruses has been rare. Of 55 strains of H5N1 virus 
from Australia and South-East Asian countries 
analyzed between 2004-2006, 53 were sensitive 
to neuraminidase inhibitors with half maximal 
inhibitory concentration (IC50) values that were 
similar to those for H1N1 strains circulating in 
this region between 2001 and 2006, and the 
two less sensitive strains had IC50 values of 
5.38 and 3.59 nmol/L, which would be expected 
to be sensitive to oseltamivir treatment at 
recommended doses.113 A more recent analysis 
of H5N1 genome sequences that found five of 
676 isolates had potential resistance mutations 
(N294S, one; H275Y, four) predicted susceptibility 
to oseltamivir in >99% of circulating H5N1 
strains, and concluded that drug-resistant strains 
typically arose through independent point 
mutations in the neuraminidase.114 Patients from 
Vietnam and Egypt from whom oseltamivir-
resistant viruses were isolated with N294S and/
or H275Y mutations have been described in 
published case reports.115-117 Currently, the 
incidence of selection of resistance during 
treatment of H5N1 infection with oseltamivir is 
low, and appears similar to that observed during 
treatment of seasonal virus infections.
Resistance in Pandemic Influenza (H1N1) 
2009 Viruses 
Statistics from WHO published in August 2010 
show that the pandemic (H1N1) 2009 virus was 
the predominant influenza strain worldwide 
from week 20, 2009 (mid-April) until the end 
of week 5, 2010 (early February), ie, throughout 
both the southern hemisphere and northern 
hemisphere winter seasons.118 Other influenza 
viruses (particularly type B) were equally or more 
prevalent from mid-February onwards. Thus, 
the seasonal H1N1 subtypes with naturally-
acquired resistance to oseltamivir described 
above have almost disappeared from the 
circulating influenza virus population globally, 
to be replaced mainly by pandemic (H1N1) 
2009 viruses. Resistance to oseltamivir in the 
pandemic (H1N1) 2009 virus has thus far been 
sporadic and geographically dispersed, with no 
evidence that the resistant strains are circulating 
within communities.15 The great majority 
(>99%) of over 20,000 clinical specimens or 
isolates of the pandemic (H1N1) 2009 virus 
tested across the six international WHO regions 
(over 85 countries) up to February 2010 were 
sensitive to oseltamivir, as shown in Table 4.15
The pandemic (H1N1) 2009 virus is 
antigenically and genetically distinct from 
the oseltamivir-resistant seasonal influenza A 
(H1N1) virus, with a genetic make-up from North 
American and Eurasian swine virus lineages.119
No evidence of re-assortment between pandemic 
(H1N1) 2009 and other seasonal influenza 
viruses has been found.15
From April 2009 to August 2011, the 
cumulative total of oseltamivir-resistant 
pandemic (H1N1) 2009 viruses reported to WHO 
was 566.120 Considering just the 436 cases for 
which information on clinical background was 
reported, most (305 [70%]) were in patients with 
normal immune function, and 131 (30%) were 
in immunosuppressed patients. In the patients 
with normal immune function, 210 cases were 
associated with drug use (for treatment or PEP), 
and 95 cases were not associated with any drug 
use (Figure 2).120
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Prolonged viral replication and lack 
of immune-mediated virus clearance in 
immunosuppressed patients treated with 
antivirals can result in a higher incidence 
of selection of drug-resistant viruses, a 
phenomenon that has been documented 
previously.121 Surveillance of 1608 hospitalized 
patients with pandemic (H1N1) 2009 influenza 
in Edinburgh and Glasgow found resistant virus 
in 10 patients (all immunocompromised) in a 
2-month period.122 A few of the resistant isolates 
of pandemic (H1N1) 2009 collected from 
immunosuppressed patients have occurred 
in clusters, such as the hospital outbreaks in 
Cardiff, UK and Duke University, US, and are 
believed to have involved person-to-person 
transmission.15 A report from an Australian 
group describes four immunocompromised 
patients with resistant influenza virus, most of 
whom acquired infections in the community 
rather than nosocomially.123 Influenza isolates 
obtained from two immunocompromised 
patients infected with pandemic (H1N1) 
2009 influenza identified a new mutation in 
the neuraminidase (I223R), either alone or 
in combination with H275Y, that can confer 
moderate resistance to both oseltamivir and 
zanamivir.124,125
As of August 18, 2010, 6% of all cases of 
oseltamivir resistance reported to WHO were 
in individuals with normal immune function 
who received oseltamivir as prophylaxis, and 
additional (unquantified) cases of resistance 
have been reported in immunosuppressed 
patients on a prophylactic regimen.126
Table 4. Number of oseltamivir-resistant pandemic (H1N1) 2009 isolates in each World Health Organization (WHO) 
region, compared with number of isolates and clinical specimens tested for susceptibility, as of February 15, 2010.15
WHO region Resistant isolates Total tested
Africa 0 66
Eastern Mediterranean 1 50
Europe 77 >7500
Americas 65 >8000
South-East Asia 0 20






Normal immune function; drug-associated
Normal immune function; non-drug-associated
Preliminary report or insucent data
Figure 2. Breakdown by clinical setting of cases of 
oseltamivir-resistant viruses reported to World Health 
Organization up to August 10, 2011.121
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Case reports on some of these individuals have 
been reported separately.127-129
The low number of oseltamivir-resistant 
viruses in patients with pandemic (H1N1) 2009 
influenza is consistent with lower fitness and/or 
transmissibility of the resistant variants compared 
with the sensitive variants of the virus. Reduced 
transmissibility of H1N1 viruses carrying a single 
H275Y point mutation in the neuraminidase 
coding sequence has been described previously 
for seasonal H1N1 viruses.15,98 Additional 
compensatory mutations are expected to be 
required to allow more efficient replication or 
transmission of oseltamivir-resistant viruses. 
Data from animal studies on pandemic (H1N1) 
2009 viruses suggested that resistant strains have 
either reduced transmissibility or similar fitness 
and transmissibility compared with sensitive 
strains.130-132 The reasons for the differences in 
observations are unclear, but may be related 
to the use of different virus strains in these 
studies, or the low number of animals used. The 
possibility of natural emergence of compensatory 
mutations or compensated resistance mutations 
to neuraminidase inhibitors warrants continued 
close surveillance of sequence evolution in 
influenza viruses.
SAFETY
Safety in Adults and Adolescents Established 
in Controlled Clinical Trials 
Cumulative safety and tolerability data for 
oseltamivir use in adults and adolescents in 
randomized controlled trials come from 4592 
study participants exposed to oseltamivir, 2647 
of whom received it as treatment and 1945 of 
whom received it for influenza prophylaxis. 
Clinical trial experience in children and other 
groups is described below (see Safety in Special 
Populations). In treatment studies, the most 
frequently reported AEs were nausea, vomiting, 
and headache. The majority of these events 
were reported on a single occasion, usually on 
the first or second treatment day, and resolved 
spontaneously within 1-2 days without the 
need to stop treatment. In prophylaxis studies, 
the safety profile was similar, despite a longer 
duration of dosing: nausea, vomiting, headache, 
and pain were the most frequently reported 
AEs (Table 5). Other AEs were reported in ≥1% 
of oseltamivir recipients in the treatment 
and prophylaxis studies, but at a similar 
or lower incidence compared with placebo 
recipients. These included many symptoms 
and complications that are typical of influenza 
infection, including nasal congestion, cough, 
sore throat, muscular or joint pain, diarrhea, 
abdominal pain, fatigue, and dizziness, as well 
as infections (such as bronchitis and upper 
respiratory tract infections), dysmenorrhea, and 
insomnia (Roche, data on file).
Post-Marketing Surveillance 
Other AEs in people receiving oseltamivir 
have been identified from spontaneous 
reports received during post-marketing use. 
Hypersensitivity reactions, many of which 
were allergic skin reactions, such as dermatitis, 
eczema, erythema multiforme, Stevens-Johnson 
syndrome (SJS), and toxic epidermal necrolysis 
have been reported.6,7,133 Hepatitis and elevated 
liver enzymes have also been reported in 
patients with ILI receiving oseltamivir, and cases 
of gastrointestinal bleeding.6,7
Two recent reports described a possible 
associat ion between oseltamivir  and 
cardiovascular effects. In the first report, torsades 
de pointes (a form of ventricular tachycardia) 
occurred in two women who had been 
previously treated with sotalol for arrhythmias 
and were given oseltamivir for confirmed or 
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suspected influenza; in one of these women, the 
causative relationship was doubtable, occurring 
6 days after treatment finished, although 
prolongation of the QT interval corrected 
for heart rate (QTc) was observed during the 
treatment course.134 In the second report, two 
women treated with oseltamivir for suspected 
pandemic (H1N1) 2009 influenza developed 
bradycardia.135 The results of a retrospective 
cohort study, however, suggest that the risk 
of recurrent adverse cardiovascular outcomes 
such as heart failure and sudden cardiac death 
in patients with existing cardiovascular disease 
is lower in those treated with oseltamivir than 
those not treated,136 and a similar benefit 
has been shown with respect to stroke and 
transient ischemic attacks.137 An expert review 
of data from preclinical and clinical studies, 
published literature, and spontaneous reports 
in the Roche Drug Safety database indicates no 
association between oseltamivir treatment and 
cardiac arrhythmias, other cardiac disorders, 
or sudden death in adults or children, and no 
increased susceptibility to cardiac events in 
Japanese individuals (Hoffmann-La Roche, data 
on file). 
Table 5. Adverse drug reactions reported in ≥1% of patients in the oseltamivir group in studies investigating oseltamivir for 
the treatment or prevention of influenza in adults and adolescents and in post-marketing surveillance (pooled analysis).6
Proportion of patients (%) who reported events
Treatment Prevention
Oseltamivir 75 mg 
twice daily (n=1057) Placebo (n=1050)
Oseltamivir 75 mg 
once daily (n=1480) Placebo (n=1434)
Bronchitis 4 5 1 1
Bronchitis acute 1 1 0 <1
Upper respiratory tract infection 0 0 8 8
Headache 2 2 20 18
Insomnia 1 1 1 1
Vertigo 1 1 <1 <1
Cough 1 1 6 6
Rhinorrhea <1 0 2 1
Nausea*† 11 7 8 4
Vomiting† 8 3 2 4
Abdominal pain 2 2 2 2
Diarrhea 6 8 3 3
Dyspepsia 1 1 2 2
Dermatitis <1 <1 1 1
Dizziness 2 3 2 2
Fatigue 1 1 8 8
Pain <1 <1 4 3
*Subjects who reported nausea alone (without vomiting).
†Statistically significant difference between oseltamivir and placebo.
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Neuropsychiatric AEs 
Various neuropsychiatric AEs (NPAEs) have been 
reported during oseltamivir administration, mainly 
in children and adolescents. These have included 
convulsions as well as delirium-like symptoms, 
such as altered consciousness, confusion, abnormal 
behavior, delusions, hallucinations, agitation, 
anxiety, and nightmares, and in some cases, have 
resulted in accidental injury. Although NPAEs were 
described in patients with influenza infection before 
the introduction of oseltamivir,138-140 reports of such 
events during 2005-2006, principally in Japanese 
patients, suggested that they were associated with 
oseltamivir treatment.141 In January 2008, the US 
product label was changed following guidance from 
the Pediatric Advisory Committee of the US Food 
and Drugs Administration; the changes included 
a description of neuropsychiatric symptoms that 
can occur during influenza infection, irrespective 
of drug therapy, and noted the uncertain causality 
of such symptoms. The new labeling also notes that 
symptoms can appear abruptly and that “injurious 
behavior” includes fatal outcomes. Similar labeling 
changes were recommended for other antiviral 
influenza medications.
In 2008, Roche published an assessment of 
influenza-associated NPAEs in patients who had 
received oseltamivir.103 The article included a 
wide range of evaluations aimed at assessing the 
prevalence and genesis of such events. It included 
post-marketing surveillance of spontaneously 
reported AEs, prospective clinical trial data, 
and results of large retrospective observational 
studies based on US health claims data. This was 
supplemented by results of pharmacokinetic 
studies in humans and animals, analysis of possible 
genetic factors, and pharmacodynamic interactions 
with neurotransmitter and transport mechanisms 
and metabolic pathways. The article concluded 
that the data then available did not indicate that 
oseltamivir administration increased the risk of 
NPAEs in influenza patients, and no mechanism 
through which oseltamivir or its metabolites could 
cause or aggravate such events could be identified, 
although a contribution from the drug could not 
be conclusively ruled out at that stage.103 More 
recently, an additional analysis of a large patients 
claims database produced results consistent with 
those summarized in the review by Toovey et 
al.,103 showing that influenza patients treated with 
oseltamivir had a lower risk of NPAEs than patients 
who receive no antiviral treatment.142
In early 2010, a new comprehensive safety 
evaluation on oseltamivir was performed, to 
determine whether any new safety signals 
emerged during the period when pandemic 
(H1N1) 2009 virus was the dominant strain, and 
to assess tolerability and safety in the patient 
sub-populations that had been underexposed to 
oseltamivir up to that point.143 This evaluation 
compared reports of AEs in the US and Japan 
during the first 8 months of the 2009 influenza 
pandemic (May 1-December 31, 2009) with 
post-marketing reports during the pre-pandemic 
period, ie, before May 1, 2009. The analysis did 
not indicate that any new safety signals emerged 
during the pandemic period, and also showed 
that NPAEs were significantly less common (crude 
reporting rates per million exposures) during the 
pandemic than the pre-pandemic period.143
Safety in Special Populations
Children
Safety data on children aged 1-12 years with 
seasonal influenza have demonstrated that 
oseltamivir is well tolerated with a similar AE 
profile to placebo (Table 6). In a pooled analysis 
of four treatment studies in 1032 children given 
the 2 mg/kg dose twice daily for 5 days, the only 
events that occurred more frequently in the 
oseltamivir group were vomiting (15% vs. 9%), 
abdominal pain (5% vs. 4%), and ear disorders 
Adv Ther (2011)  28(11):927-959. 947
(2% vs. 1%), with the gastrointestinal events 
usually occurring at the start of treatment and 
resolving rapidly.144 Gastrointestinal symptoms 
were also the most commonly reported events 
in two prophylaxis studies, where treatment 
duration was either 10 days or 6 weeks, and 
the AEs seen were generally mild to moderate 
in intensity.43,145
In May 2009, the typical circulating seasonal 
influenza strains including H1N1 viruses were 
almost completely replaced by pandemic (H1N1) 
2009 virus. Regulatory bodies in the US and 
Europe responded to this development by giving 
emergency use authorization (EUA) for the use of 
oseltamivir in additional patient groups, including 
infants <1 year old.146,147 The decision made by the 
European Medicines Agency (EMA) in September 
2009 to approve treatment and prevention 
indications in infants <1 year of age was based on 
a review by the Committee for Medicinal Products 
for Human Use (CHMP).146 The data reviewed by 
CHMP included interim pharmacokinetic and 
safety data from the prospective study, CASG114, 
(US National Institutes of Health; ClinicalTrials.
Table 6. Adverse drug reactions reported in ≥1% of patients in the oseltamivir group in studies investigating oseltamivir for 
the treatment or prevention of influenza in children and in post-marketing surveillance (pooled analysis).6 
Proportion of patients (%) who reported events
Treatment Treatment Prevention*








Oseltamivir 30-75 mg 
twice daily† 
(n=148)
Pneumonia 2 3 0 0
Bronchitis 2 3 0 <1
Sinusitis 2 2 2 0
Otitis media 9 11 1 2
Lymphadenopathy 1 2 <1 0
Cough 1 1 3 12
Nasal congestion <1 <1 2 11
Asthma (aggravated) 4 4 0 1
Epistaxis 3 3 1 <1
Vomiting 15 9 20 8
Diarrhea 10 11 3 <1
Nausea 3 4 6 4
Abdominal pain 5 4 2 1
Conjunctivitis 1 <1 0 0
Ear disorder‡ 2 1 0 <1
Tympanic membrane disorder 1 1 0 0
Dermatitis 1 2 <1 0
*This study had no placebo arm.
†Weight-based dosing.
‡Earache and pain in the ear.
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gov identifier: NCT00391768) in children aged 
<2 years, safety data from Japanese interventional 
and surveillance studies, and a German hospital 
study (see below). On the strength of these data it 
was concluded that the benefit of using oseltamivir 
for the treatment and PEP of infants <1 year old 
outweighed the risk in the context of pandemic 
influenza. Recommendations for updating the 
product’s label were therefore made, including 
dosages to treat children 0-6 months old who are 
infected with pandemic influenza, and to prevent 
illness in children <1 year old who are exposed 
to pandemic influenza.146 Since the EMA’s review, 
the results of the German hospital study in infants 
aged <1 year has been published. This retrospective 
analysis showed that oseltamivir was generally 
well tolerated: only one of the 157 infants 
failed to complete the 5-day oseltamivir course 
because of an AE (repeated vomiting), and AEs 
were seen in 78 (50%) infants, the majority being 
vomiting or diarrhea of mild intensity.148
The Roche safety evaluation that assessed 
tolerability and safety of oseltamivir during the 
first 8 months of the 2009 influenza pandemic 
(see Neuropsychiatric AEs) evaluated four 
patient sub-populations, one of which was 
infants <1 year old. Spontaneous AEs from the 
Roche database and serious adverse events (SAEs) 
from clinical trials during the period of May 
1-December 31, 2009 were medically reviewed. 
During this period, 107 events were reported in 
74 infants, one of whom died (from influenza 
complicated by ARDS/viral pneumonia). Of 
24 other (non-fatal) SAEs, the associated terms 
were either typical findings in infants with febrile 
viral infections, like rashes and convulsions, or 
considered to be related either to other current 
illness or medications.143
Pregnant Women 
The decision to recommend the use of oseltamivir 
in pregnant and lactating women in the context 
of pandemic (H1N1) 2009 influenza147,149
was based on the results of an analysis of 232 
maternal exposures to oseltamivir during 
pregnancy from Roche’s safety database.150 That 
analysis has since been substantially expanded as 
a result of the increased use of oseltamivir during 
the 2009-2010 pandemic. This assessment of 
1335 maternal exposures over a 10-year period, 
where pregnancy and fetal outcomes were 
known for 618 and 569 women, respectively, 
suggests that oseltamivir is unlikely to cause 
adverse pregnancy outcomes (spontaneous and 
therapeutic abortions and pre-term delivery) 
or fetal outcomes (birth defects) (Roche, data 
on file). These results were in line with those 
of a retrospective analysis by a US group who 
assessed the safety of antiviral agents during 
pregnancy by comparing 239 mothers exposed 
to these agents with roughly 82,000 unexposed 
controls, and found no effect on maternal and 
neonatal outcomes of antepartum exposure to 
oseltamivir or M2 ion channel inhibitors, such 
as amantadine.151 The pandemic-specific safety 
evaluation referred to above also reviewed data 
on pregnant women, and found no evidence of 
AEs of oseltamivir in 207 maternal exposures.143
Immunocompromised Individuals
Two groups have reported safety and tolerability 
data on oseltamivir in immunocompromised 
patients in the seasonal influenza setting. In the 
first of these,152 the AE profile in 45 individuals 
aged 11-73 years who were undergoing 
hematopoietic stem cell transplantation (HSCT) 
and received oseltamivir as post-exposure 
prevention following an influenza outbreak was 
similar to that in matched untreated controls; 
most of the events reported were gastrointestinal 
symptoms, such as nausea and vomiting, and 
the incidence of these was similar to controls, 
although abdominal pain was more common in 
the treated group. No deaths were attributable 
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to oseltamivir.152 In a later study in solid organ 
and HSCT recipients receiving a 12-week 
oseltamivir course for seasonal influenza 
prevention, the incidence of AEs and SAEs was 
found to be very similar for oseltamivir and 
placebo, with gastrointestinal disorders again 
being the most frequent AEs recorded.153
A recent report from the Memorial Sloan-
Kettering Cancer Center provides evidence of 
tolerability in immunocompromised patients 
with pandemic influenza. The patients in this 
study (age range, 3-80 years; 13 aged <18 years) 
had hematological cancers or solid tumors, 
and some had also received HSCT; all were 
positive for pandemic (H1N1) 2009 influenza. 
In the 43 patients who received oseltamivir at 
a dose of 75 mg twice daily or the equivalent 
pediatric dose for 5 days (or for 8 and 17 days 
in two patients with prolonged shedding 
or symptoms), treatment was well tolerated 
and no patients died or required mechanical 
ventilation.154 These findings are supported 
by a case report on two kidney transplant 
recipients who had complicated pandemic 
(H1N1) 2009 influenza infections, in whom 
prolonged high-dose oseltamivir treatment was 
well tolerated.155 Additionally, no new safety 
signals were detected in immunocompromised 
patients exposed to oseltamivir during the 2009 
pandemic outbreak.143
Elderly Patients
The pooled analysis of oseltamivir treatment 
studies mentioned above also included a 
comparison of AE incidence between elderly 
adults aged ≥65 years and adults <65 years 
old; the only differences were that elderly 
treated patients reported a lower incidence of 
nausea and vomiting and a higher incidence of 
dyspepsia.144 The safety of oseltamivir was also 
evaluated in the study of influenza prevention in 
frail elderly patients by Peters et al.,45 who found 
similar safety profiles in the treated and placebo 
arms, including a relatively low incidence of 
diarrhea, nausea, and vomiting (all <5%). The 
evaluation of safety during the 2009 pandemic 
outbreak did not reveal any new safety signals 
in 189 elderly patients exposed to oseltamivir.143
High-Dose Oral Administration
Infections with pandemic (H1N1) 2009 and 
H5N1 viruses can give rise to a severe influenza 
that may not respond to standard antiviral 
treatment regimens, and the efficacy of extended 
treatment courses and higher daily doses for 
influenza treatment is being tested in current 
clinical trials. An indication of how higher 
oseltamivir doses might be tolerated is provided 
by a study in which 194 healthy volunteers 
received doses of 225 and 450 mg twice daily 
for 5 days; no evidence of drug accumulation 
was found, and although nausea, vomiting, 
and dizziness were more common at the higher 
doses than standard dose, tolerability was good, 
with no adverse safety findings.156
I.V. Administration
In January 2010, the EMA CHMP announced 
that an i.v. presentation of oseltamivir could 
be used on compassionate use grounds for 
the treatment of critically ill patients with 
influenza infection who do not respond to, 
or cannot be given, neuraminidase inhibitor 
treatment either orally or by inhalation. As of 
February 2011, approximately 50 treatment 
packs had been issued. Roche-sponsored 
clinical studies are ongoing to establish 
the safety and tolerability of intravenously 
administered oseltamivir in infected infants 
aged 0-1 years (NCT01053663), children aged 
1-12 years (NCT01033734), and adults and 
adolescents aged ≥13 years (NCT01050257).
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PHARMACOECONOMICS
For the 10 years during which oseltamivir 
has been available, several studies have been 
performed to evaluate the pharmacoeconomics 
of the drug in a range of patient populations. 
These have mostly measured the cost-
effectiveness or cost-benefit of oseltamivir 
as an influenza treatment, compared with 
interventions such as vaccination and “usual 
care” regimens (simple analgesics and cough 
remedies), and occasional reviews of the 
accumulating evidence base have helped to 
assess the range of economic benefits that can 
be achieved.157-159 The review of oseltamivir 
and zanamivir by Lynd et al.158 showed that 
the former was cost-saving from a societal 
perspective and cost-effective from a healthcare-
only perspective, but the authors highlighted 
the variability in methods and assumptions 
used in the studies which were reviewed, and 
how this limited the scope of the conclusions. 
The systematic review of 2008 by Postma 
and colleagues took a different viewpoint, 
by measuring how cost-effective oseltamivir 
was relative to usual influenza care regimens. 
The authors discovered limitations in some of 
the analytical methods used and the range of 
assumptions made - for example, most papers 
that the authors selected failed to describe clearly 
how altering the disease valuation (willingness-
to-pay value) affected the results of the study’s 
analyses, and although most papers in the review 
assessed economic benefit by using decision 
models, the important assumptions behind the 
models varied widely, such as the expected rate 
of confirmed influenza in individuals presenting 
with ILI, and the amount of work-time lost 
to illness. Nevertheless, the authors found 
that oseltamivir treatment was cost-effective 
relative to usual care in the four population 
groups studied (adults and adolescents, children 
>15 years of age, elderly patients, and those in 
high-risk groups).159
Decision models continue to be the basis for 
economic analysis in some more recent studies. 
One group who assessed cost-effectiveness 
of oseltamivir used as PEP from the United 
Kingdom (UK) healthcare payer’s perspective 
showed that the intervention would be cost-
effective compared with a usual-care treatment 
strategy if SARs in household contacts were 
≥8%.160 Other groups have examined cost-
effectiveness in the treatment setting. An 
analysis that compared oseltamivir treatment 
for ILI with usual care in the Netherlands 
focused on patients at elevated risk of serious 
complications from influenza infection; the 
study found that, from the societal perspective, 
oseltamivir was cost-saving for chronically 
ill adults (of any age) and cost-effective 
(€1759 per life-year gained) for otherwise 
healthy elderly patients.161 A US group used a 
decision-analysis model to confirm the findings 
of the 2008 Postma et al.159 review, ie, that 
treatment of ILI with oseltamivir was cost-
effective compared with usual care in high-
risk adults, healthy adults, elderly adults, and 
children, from both the societal and healthcare 
payer perspectives.162 Notably, the authors 
analysis assumed that treatment would be 
ineffective if given later than 48 hours after 
symptom onset or in individuals infected with 
virus resistant to oseltamivir. A recent study on 
the cost-effectiveness of oseltamivir treatment 
in Japan also investigated the effects of 
emerging resistance on economic benefit. The 
authors found that, from a healthcare payer’s 
perspective, the cost per quality-adjusted life 
year (QALY) gained was US$3320 and, from 
a societal perspective (considering the cost of 
lost work time), oseltamivir was dominant; 
however, if the incidence of resistant virus 
exceeded 27%, oseltamivir was no longer 
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dominant. Allowing for the emergence of 
resistance and other uncertainties, the authors 
calculated an 80% probability that the drug 
would be cost-effective at a willingness-to-pay 
level of US$50,000/year.163
Most recently, the economic benefits of 
antiviral therapies have been evaluated in the 
setting of pandemic mitigation. Before and 
during the 2009 pandemic, pandemic response 
strategies attracted much attention, but as with 
the simpler cost-effectiveness question above, 
the relative benefits of each mitigation measure 
depended closely on assumptions about, for 
example, the virulence of the pandemic virus 
and how quickly and widely the pandemic 
would spread. The most commonly evaluated 
mitigation measures to date are treatment 
and/or prophylaxis with stockpiled antivirals, 
vaccination, school closures, and travel 
restrictions. In a review of 12 studies on this 
topic by Lugner and Postma,164 five studies that 
specifically evaluated stockpiling of antiviral 
drugs showed that this measure would be 
cost-effective assuming it was used to treat 
symptomatic individuals, and could also be 
cost-effective if used for prophylaxis in some 
scenarios. This review also discussed the merits 
of dynamic models, ie, those that measure 
disease transmission, in relation to static or 
decision-tree models for valuation assessments, 
and concluded that dynamic models produce 
a more valid estimate of cost-effectiveness. 
One of the studies reviewed by Lugner and 
Postma that used this approach (a stochastic 
transmission model) to evaluate a range of 
mitigation measures, fully accounting for the 
cost of stockpiling and delivery of antivirals, 
was the analysis by Sander et al.165 This study 
demonstrated that full targeted antiviral 
prophylaxis (FTAP), ie, coverage of household 
contacts as well as 60% of work and school 
contacts, was the most effective single strategy, 
slightly outperforming pre-vaccination and 
more restricted antiviral prophylaxis measures 
- FTAP reduced the number of cases by 54% at 
a cost of $127 to society.165
CONCLUSIONS 
In the period of just over 10 years since 
oseltamivir was introduced, it has proved to be 
an effective, safe, and valuable antiviral agent 
for the management of influenza infections in 
many settings. Early clinical trials in patients 
with mild disease showed that treatment 
could lessen symptom severity, shorten illness 
duration, and reduce the risk of complications, 
and that preventative use could protect against 
illness, but recent studies in seriously ill patients 
have demonstrated its value in avoiding more 
severe outcomes, including death; the latter 
evidence includes experience in avian H5N1 
influenza and pandemic (H1N1) 2009 influenza. 
Natural resistance to oseltamivir in the H1N1 
seasonal virus strain emerged in 2007, but this 
strain virtually disappeared after the arrival of 
the novel H1N1 strain that caused the 2009 
pandemic. Drug-induced resistance remains 
very rare, and oseltamivir has proved to be well 
tolerated by all population groups.
New research now under way will provide 
more information on the efficacy and safety 
profile of oseltamivir in vulnerable population 
groups, such as very young infants and 
immunocompromised patients, as well as in 
severely ill patients in the ICU setting. Some 
studies will investigate resistance in more detail, 
and others will assess the effectiveness of high-
dose treatment regimens, particularly in patients 
with avian H5N1 influenza.
Despite WHO having declared in August 2010 
that the 2009 influenza pandemic outbreak has 
ended and the post-pandemic stage has started, 
influenza will remain a serious challenge for 
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healthcare professionals. New emergencies are 
inevitable, including the possible evolution of 
avian H5N1 and other influenza viruses into 
strains with more efficient human-to-human 
transmissibility. The threat from influenza has 
evolved in the 10 years since the arrival of 
oseltamivir, and it is certain that the threat will 
continue to evolve in the future.
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